scispace - formally typeset
S

Susanne K. Kjaer

Researcher at University of Copenhagen

Publications -  674
Citations -  41997

Susanne K. Kjaer is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 90, co-authored 636 publications receiving 36979 citations. Previous affiliations of Susanne K. Kjaer include Copenhagen University Hospital & McGill University.

Papers
More filters
Journal ArticleDOI

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

TL;DR: The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination, and effectiveness in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results.
Journal ArticleDOI

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Catherine M. Phelan, +443 more
- 01 May 2017 - 
TL;DR: Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.
Journal ArticleDOI

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

Honglin Song, +89 more
- 01 Sep 2009 - 
TL;DR: A genome-wide association study to identify common ovarian cancer susceptibility alleles was performed, identifying 12 SNPs at 9p22 associated with disease risk and the most significant SNP was genotyped in 2,670 ovarian cancer cases and 4,668 controls.
Journal Article

High-Risk Human Papillomavirus Is Sexually Transmitted: Evidence from a Follow-Up Study of Virgins Starting Sexual Activity (Intercourse)

TL;DR: The results show that sexual intercourse is important in the transmission of HPV, and that HPV 16 VLP seroconversion and the development of cervical lesions only occur after HPV transmission, and no cervical lesions were found in HPV 16 DNA positive women who had seroconverted.
Journal ArticleDOI

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

TL;DR: The 9vHPV vaccine prevents infection, cytological abnormalities, high-grade lesions, and cervical procedures related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV).